Skip to main content

Table 1 Characteristics of Black and White breast cancer patients by cancer subtype, New Castle County, DE

From: Racial disparities in triple negative breast cancer: toward a causal architecture approach

 

TNBC

(N = 453)

Non-TNBC

(N = 2863)

Total

(N = 3316)

p-values

Age at diagnosis, mean (SD)**

60.2 (14.6)

63.0 (13.2)

62.6 (13.4)

 < 0.001

Race, n (%)**

 < 0.001

 White

274 (60.5)

2266 (79.1)

2540 (76.6)

–

 Black/African American

179 (39.5)

597 (20.9)

776 (23.4)

–

Insurance, n (%)*

 

0.015

 Private

251 (55.4)

1470 (51.3)

1721 (51.9)

0.468

 Medicare†

162 (35.8)

1207 (42.2)

1369 (41.3)

0.041

 Medicaid/none

37 (8.2)

156 (5.4)

193 (5.8)

0.120

 Unknown

3 (0.7)

30 (1.0)

33 (1.0)

1.000

Stage of diagnosisa, n (%)**

 < 0.001

 Early stage††

381 (84.1)

2637 (92.1)

3018 (91.0)

 < 0.001

 Late stage††

67 (14.8)

205 (7.2)

272 (8.2)

 < 0.001

 Unknown stage

5 (1.1)

21 (0.7)

26 (0.8)

1.000

Census tract ICE-Race, n (%)**

 < 0.001

 Q1†† (most disadvantaged)

104 (23.0)

367 (12.8)

471 (14.2)

 < 0.001

 Q2

102 (22.5)

585 (20.4)

687 (20.7)

1.000

 Q3

103 (22.7)

694 (24.2)

797 (24.0)

1.000

 Q4

95 (21.0)

621 (21.7)

716 (21.6)

1.000

 Q5†† (most advantaged)

49 (10.8)

596 (20.8)

645 (19.5)

 < 0.001

Census tract ICE-Income, n (%)**

 < 0.001

 Q1†† (most disadvantaged)

80 (17.7)

359 (12.5)

439 (13.2)

0.028

 Q2

96 (21.2)

487 (17.0)

583 (17.6)

0.298

 Q3

64 (14.1)

475 (16.6)

539 (16.3)

1.000

 Q4

114 (25.2)

699 (24.4)

813 (24.5)

1.000

 Q5†† (most advantaged)

99 (21.9)

843 (29.4)

942 (28.4)

0.009

Census tract ICE-Race/Income, n (%)**

 < 0.001

 Q1†† (most disadvantaged)

82 (18.1)

329 (11.5)

411 (12.4)

0.001

 Q2

112 (24.7)

547 (19.1)

659 (19.9)

0.054

 Q3

77 (17.0)

562 (19.6)

639 (19.3)

1.000

 Q4

94 (20.8)

693 (24.2)

787 (23.7)

1.000

 Q5†† (most advantaged)

88 (19.4)

732 (25.6)

820 (24.7)

0.049

  1. aEarly stage includes stages 1-3a and late stage includes stages 3b-4
  2. *Significant at p < 0.05
  3. **Significant at p < 0.001
  4. †Post-hoc test significant at p < 0.05
  5. ††Significant at p < 0.001